In the realm of precision medicine, advancements in gene editing technologies targeting genetic susceptibility genes, such as patatin-like phospholipase domain-containing 3 (PNPLA3) and 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13) [186], alongside immunomodulation and hepatocyte regeneration therapies utilizing mesenchymal stem cells and their secretion of extracellular vesicles (EVs), represent a novel therapeutic approach for the reversal of liver fibrosis [183]. This evidence concerns the gene HSD17B13 and Hepatic fibrosis.